NEOS Investment Management LLC Purchases 23,291 Shares of Boston Scientific Corporation $BSX

NEOS Investment Management LLC increased its position in Boston Scientific Corporation (NYSE:BSX) by 10.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 243,837 shares of the medical equipment provider’s stock after purchasing an additional 23,291 shares during the period. NEOS Investment Management LLC’s holdings in Boston Scientific were worth $10,407,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BSX. BlackRock Inc. purchased a new stake in shares of Boston Scientific in the 2nd quarter worth about $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Norges Bank purchased a new stake in Boston Scientific during the 4th quarter valued at $2,199,395,000. Jupiter Topco LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth $803,357,000. Finally, Bank of America Corp DE purchased a new position in shares of Boston Scientific in the second quarter worth $556,026,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BSX shares. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. TD Cowen reissued a “buy” rating and issued a $56.00 target price on shares of Boston Scientific in a research report on Tuesday, August 25th. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Oppenheimer dropped their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 27th. Finally, Mizuho reduced their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

NYSE BSX opened at $47.85 on Friday. The company has a market capitalization of $69.35 billion, a PE ratio of 19.37, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The business’s fifty day moving average is $46.90 and its 200 day moving average is $55.74. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the business posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Insiders Place Their Bets

In other news, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.